Jun92022UncategorizedCategory: UncategorizedBy Charlotte Maddalena9 June 2022 Author: Charlotte Maddalena Post navigationPreviousPrevious post:Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancerNextNext post:First patient included under the French Early Access Program granted to ORPHELIA Pharma for KIMOZO®Related PostsORPHELIA Pharma collaborates with Oscar Lambret clinical center11 June 2024ORPHELIA Pharma recrute un/une Chef de Projet Réglementaire Senior7 June 2024ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®22 May 2024Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024Six new projects supported by our Foundation18 March 2024Four houses for the FAOMA call for projects18 March 2024
ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®22 May 2024
Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024
